Lv1
32 积分 2022-08-30 加入
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
12小时前
待确认
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
1个月前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
1个月前
已完结
Targeting the Stromal-Immune Barrier: A Novel Strategy to Overcome Resistance to CLDN18.2/CD3 Bispecific T-Cell Engager Therapy in Pancreatic Cancer
1个月前
已关闭
Identification and analysis of NAC genes related to S-alk(en)yl cysteine sulfoxides (CSOs) biosynthesis in Onion (Allium cepa L.)
2个月前
已完结
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
3个月前
已完结
Clinicopathological and molecular features of claudin-18 isoform 2 expression in patients with colorectal cancer: a single-center retrospective study
6个月前
已完结
Bivalent anti-CD3 Fab dimers drive T cells into a highly efficient fratricide with potential clinical application
6个月前
已关闭
Tarlatamab: First Approval
8个月前
已完结
Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism
8个月前
已完结
皖公网安备34019202002308
